The manuscript reports detailed preclinical data characterizing the potency and selectivity of BLU-667 against oncogenic RET variants and resistant mutants and anti-tumor activity in multiple
More From BioPortfolio on "Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical ..."